JCO-话题@MedSci

#JCO#

724篇内容 | 6874人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1891646, encodeId=9aea1891646c3, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：辅助化疗对HER2阳性乳腺癌老年患者生活质量的影响, objectType=article, longId=209810, objectId=5d9620981043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d9620981043, replyNumber=0, likeNumber=80, createdTime=2021-12-12, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d9620981043, moduleTitle=JCO：辅助化疗对HER2阳性乳腺癌老年患者生活质量的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d9620981043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891629, encodeId=93e418916290b, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：帕博利珠单抗单药一线治疗晚期非透明细胞肾癌的客观缓解率可达26.7％, objectType=article, longId=206735, objectId=bdea206e35cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdea206e35cc, replyNumber=0, likeNumber=66, createdTime=2021-08-12, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdea206e35cc, moduleTitle=JCO：帕博利珠单抗单药一线治疗晚期非透明细胞肾癌的客观缓解率可达26.7％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdea206e35cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891674, encodeId=4a0a18916e475, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：FOXR2可稳定MYCN蛋白，可作为神经母细胞瘤患者不良结果的独立预测因子, objectType=article, longId=212694, objectId=76ae2126945b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ae2126945b, replyNumber=0, likeNumber=63, createdTime=2021-07-04, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ae2126945b, moduleTitle=JCO：FOXR2可稳定MYCN蛋白，可作为神经母细胞瘤患者不良结果的独立预测因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76ae2126945b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891672, encodeId=b8ec18916e2fa, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1, objectType=article, longId=212671, objectId=87bb2126e1d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87bb2126e1d5, replyNumber=0, likeNumber=58, createdTime=2021-10-18, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87bb2126e1d5, moduleTitle=JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87bb2126e1d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891668, encodeId=a3f218916685a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：NRG1融合阳性肺癌的临床病理特征和对各种治疗的反应性, objectType=article, longId=212443, objectId=a7a32124431f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7a32124431f, replyNumber=0, likeNumber=77, createdTime=2022-01-30, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7a32124431f, moduleTitle=JCO：NRG1融合阳性肺癌的临床病理特征和对各种治疗的反应性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7a32124431f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891648, encodeId=9c6f1891648f3, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：Brentuximab Vedotin可显著减少高危型HL儿童患者的放疗剂量且不影响疗效, objectType=article, longId=209902, objectId=2b4f20990217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b4f20990217, replyNumber=0, likeNumber=61, createdTime=2021-05-09, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b4f20990217, moduleTitle=JCO：Brentuximab Vedotin可显著减少高危型HL儿童患者的放疗剂量且不影响疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b4f20990217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891632, encodeId=872518916327b, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期, objectType=article, longId=207011, objectId=dcad20e01104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcad20e01104, replyNumber=0, likeNumber=75, createdTime=2021-03-24, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcad20e01104, moduleTitle=JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcad20e01104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891651, encodeId=410d18916512d, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：帕妥珠单抗联合高剂量曲妥珠单抗有望改善伴有脑转移的HER2阳性乳腺癌患者的预后, objectType=article, longId=211004, objectId=c2ae2110047c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2ae2110047c, replyNumber=0, likeNumber=101, createdTime=2021-11-26, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2ae2110047c, moduleTitle=JCO：帕妥珠单抗联合高剂量曲妥珠单抗有望改善伴有脑转移的HER2阳性乳腺癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2ae2110047c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891663, encodeId=5a67189166385, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：Gemtuzumab Ozogamicin可改善KMT2A重排型AML患儿预后、减少复发！, objectType=article, longId=212166, objectId=c8ad21216642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8ad21216642, replyNumber=0, likeNumber=69, createdTime=2021-12-09, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8ad21216642, moduleTitle=JCO：Gemtuzumab Ozogamicin可改善KMT2A重排型AML患儿预后、减少复发！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8ad21216642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891641, encodeId=33c5189164124, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：口服阿扎胞苷对低风险骨髓增生异常综合征患者的影响, objectType=article, longId=209205, objectId=36c4209205ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36c4209205ac, replyNumber=0, likeNumber=91, createdTime=2021-09-14, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36c4209205ac, moduleTitle=JCO：口服阿扎胞苷对低风险骨髓增生异常综合征患者的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36c4209205ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891640, encodeId=ad54189164029, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：HER2在转移性胃癌中的表达及其对生存率的影响, objectType=article, longId=209151, objectId=483d20915154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=483d20915154, replyNumber=0, likeNumber=96, createdTime=2021-05-29, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=483d20915154, moduleTitle=JCO：HER2在转移性胃癌中的表达及其对生存率的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=483d20915154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891658, encodeId=e0df18916587a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌, objectType=article, longId=211375, objectId=15302113e548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15302113e548, replyNumber=0, likeNumber=83, createdTime=2021-07-26, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15302113e548, moduleTitle=JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15302113e548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891655, encodeId=c50a1891655e1, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：乐伐替尼或可用于治疗晚期胃肠道胰腺神经内分泌肿瘤！, objectType=article, longId=211131, objectId=ac0a21113198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0a21113198, replyNumber=0, likeNumber=72, createdTime=2022-04-09, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0a21113198, moduleTitle=JCO：乐伐替尼或可用于治疗晚期胃肠道胰腺神经内分泌肿瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac0a21113198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891638, encodeId=4a341891638e0, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：更低剂量、更好疗效——他莫昔芬让更多女性获益！, objectType=article, longId=208990, objectId=90db2089900a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90db2089900a, replyNumber=0, likeNumber=88, createdTime=2021-10-19, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90db2089900a, moduleTitle=JCO：更低剂量、更好疗效——他莫昔芬让更多女性获益！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90db2089900a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891680, encodeId=21e2189168001, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=从JCOG的数据看CT上“影像学非浸润性肺癌”的临床特点, objectType=article, longId=215638, objectId=b45c215638b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b45c215638b8, replyNumber=0, likeNumber=85, createdTime=2021-11-14, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b45c215638b8, moduleTitle=从JCOG的数据看CT上“影像学非浸润性肺癌”的临床特点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b45c215638b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891660, encodeId=e884189166050, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？, objectType=article, longId=211980, objectId=f93f211980ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f93f211980ae, replyNumber=0, likeNumber=70, createdTime=2022-04-17, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f93f211980ae, moduleTitle=JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f93f211980ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891673, encodeId=db2e18916e370, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：ALK遗传变异在高危型神经母细胞瘤中的发生率及对预后的影响, objectType=article, longId=212691, objectId=a72d21269196, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a72d21269196, replyNumber=0, likeNumber=79, createdTime=2021-07-26, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a72d21269196, moduleTitle=JCO：ALK遗传变异在高危型神经母细胞瘤中的发生率及对预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a72d21269196)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891665, encodeId=c46d189166595, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：砷联合全反式维甲酸可安全有效治疗中国APL儿科患者！, objectType=article, longId=212313, objectId=f11b2123131f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f11b2123131f, replyNumber=0, likeNumber=79, createdTime=2021-11-09, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f11b2123131f, moduleTitle=JCO：砷联合全反式维甲酸可安全有效治疗中国APL儿科患者！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f11b2123131f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891624, encodeId=958d189162422, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：造血细胞移植后发生房颤的风险及相关因素, objectType=article, longId=205700, objectId=c8ea205e00ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8ea205e00ca, replyNumber=0, likeNumber=89, createdTime=2021-07-05, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8ea205e00ca, moduleTitle=JCO：造血细胞移植后发生房颤的风险及相关因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8ea205e00ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891623, encodeId=422e189162397, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益, objectType=article, longId=205673, objectId=6fbf2056e3fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fbf2056e3fc, replyNumber=0, likeNumber=91, createdTime=2021-07-16, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fbf2056e3fc, moduleTitle=JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fbf2056e3fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

JCO

2020-05-29

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：辅助化疗对HER2阳性乳腺癌老年患者生活质量的影响

2021-12-12

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：帕博利珠单抗单药一线治疗晚期非透明细胞肾癌的客观缓解率可达26.7％

2021-08-12

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：FOXR2可稳定MYCN蛋白，可作为神经母细胞瘤患者不良结果的独立预测因子

2021-07-04

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1

2021-10-18

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：NRG1融合阳性肺癌的临床病理特征和对各种治疗的反应性

2022-01-30

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：Brentuximab Vedotin可显著减少高危型HL儿童患者的放疗剂量且不影响疗效

2021-05-09

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期

2021-03-24

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：帕妥珠单抗联合高剂量曲妥珠单抗有望改善伴有脑转移的HER2阳性乳腺癌患者的预后

2021-11-26

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：Gemtuzumab Ozogamicin可改善KMT2A重排型AML患儿预后、减少复发！

2021-12-09

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：口服阿扎胞苷对低风险骨髓增生异常综合征患者的影响

2021-09-14

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：HER2在转移性胃癌中的表达及其对生存率的影响

2021-05-29

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌

2021-07-26

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：乐伐替尼或可用于治疗晚期胃肠道胰腺神经内分泌肿瘤！

2022-04-09

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：更低剂量、更好疗效——他莫昔芬让更多女性获益！

2021-10-19

lidong40 (审核中...)

前往app查看评论内容

#JCO#

从JCOG的数据看CT上“影像学非浸润性肺癌”的临床特点

2021-11-14

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？

2022-04-17

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：ALK遗传变异在高危型神经母细胞瘤中的发生率及对预后的影响

2021-07-26

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：砷联合全反式维甲酸可安全有效治疗中国APL儿科患者！

2021-11-09

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：造血细胞移植后发生房颤的风险及相关因素

2021-07-05

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益

2021-07-16

科室
- - 订阅+
  - 更多科室
工具
服务